Entrada Therapeutics Inc. (TRDA)
NASDAQ: TRDAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TRDA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $170.30M
- EPS (TTM)
- -$3.84
- Dividend yield
- None
- 52-week range
- 4.11 – 16.45
- Day range
- 4.32 – 4.58
- Volume / Avg
- 347.92K / 401.15K
- Beta
- —
- Shares outstanding
- 39.15M
52-week range
TRDA stock today
On Nov 20, TRDA ended the session at $4.35, shedding $0.29 (6.25%), versus the S&P 500's 3.70% decline. Shares are 73.6% below their 52-week high of $16.45, set on May 6, 2026 and 5.9% above the 52-week low of $4.11, near the bottom of the past year's range. TRDA is down 57.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 57.0%.
Entrada Therapeutics has posted a net loss over the last twelve months (EPS of -$3.84), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Entrada Therapeutics
Company profileEntrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Dipal Doshi
- Headquarters
- Boston, MA
- Employees
- 152
- IPO year
- 2021
- Website
- entradatx.com
Financial highlights
Full financialsIn fiscal 2025, Entrada Therapeutics generated $25.4 million in revenue, down 87.9% from fiscal 2024, the first decline in the 6 years shown. Entrada Therapeutics reported a net loss of $143.8 million, compared with net income of $65.6 million a year earlier. Operating margin was -621.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $25.42M | $210.78M | $129.01M | — | — |
| Growth | -87.94% | +63.38% | — | — | — |
| Net income | $-143.75M | $65.63M | $-6.68M | $-94.62M | $-51.16M |
| EPS (diluted) | $-3.47 | $1.68 | $-0.20 | $-3.02 | $-8.16 |
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$17.75+308.05%
- Strong buy 0
- Buy 7
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.94 vs $-0.98
- Surprise
- +4.08%
TRDA news
All TRDA news- Entrada Advised By DMC To Introduce Cohort 3 In Phase 1/2 For Duchenne Muscular DystrophyNasdaqTRDA, BRK.A
- Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Increased Dose of 15 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 StudyGlobeNewswire
- Entrada Therapeutics Consensus Price Target Raised 24.03% to $20.81Nasdaq
- Entrada Therapeutics Reports Third Quarter 2026 Financial ResultsGlobeNewswire
- Entrada Therapeutics Appoints Linea Aspesi as Chief People OfficerGlobeNewswire
- Noteworthy Thursday Option Activity: TRDA, JBS, MCRINasdaqTRDA, JBS, MCRI
- Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 StudyGlobeNewswire
- Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45GlobeNewswire
Entrada Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SIGASIGA Technologies Inc. | 2.40 | -9.43% | $172.45M | vs TRDA |
| KRROKorro Bio Inc. | 12.18 | -0.08% | $167.18M | vs TRDA |
| ABEOAbeona Therapeutics Inc. | 2.42 | -1.22% | $165.31M | vs TRDA |
| VOGXVogenx Inc | 11.87 | -7.30% | $176.33M | vs TRDA |
| NATRNature's Sunshine Products Inc. | 10.18 | +0.10% | $176.41M | vs TRDA |
| EMISEmmis Acquisition Corp. Class A | 10.36 | +0.15% | $163.36M | vs TRDA |
| ADCTADC Therapeutics SA | 1.28 | -1.54% | $180.05M | vs TRDA |
| SLGLSol-Gel Technologies Ltd. | 55.17 | +2.02% | $180.63M | vs TRDA |
Indexes, lists and sector
Entrada Therapeutics stock FAQ
What is Entrada Therapeutics's stock price today?
TRDA last traded at $4.35 as of Nov 20, 4:00 PM EST, down 6.25% on the day. Prices are delayed at least 15 minutes.
Who is Entrada Therapeutics's CEO?
Mr. Dipal Doshi is the chief executive officer of Entrada Therapeutics Inc., which has about 152 employees.
What is the TRDA 52-week high?
The 52-week high for TRDA is $16.45 and the 52-week low is $4.11. The stock is currently 73.6% below its high.